compounding semaglutide fda enforcement news today alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA Warns on Certain Forms

Still, available evidence primarily includes retrospective observational studies, many of which rely on analysis of electronic health records and administrative claims data and are subject to limitations

Rising Adverse Events The FDA recently reported receiving serious adverse events linked to 'compounded semaglutide.' The specifics are yet to be disclosed but are expected to be released soon

The rationale given by Oguma et al

Socioeconomic status, lifestyle and risk of incident dementia: a prospective cohort study of 276730 participants

Plaintiffs claim manufacturers: Knew or should have known gastroparesis could be permanent Failed to adequately warn patients and doctors Understated the severity and duration of risk Continued aggressive marketing despite safety signals 2

While some telehealth companies have completely ceased offering tirzepatide and semaglutide, others have adjusted their offerings so that they are either in oral formats (like dissolving tablets) that are different than injectables, in custom dosages, or sold with additives like vitamin B